GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 1932-1941

  Hu, Zhenzhen ^a   Xu, Rui ^a   Liu, Jiaojing ^a   Zhang, Yujie ^a   Du, Jun ^a   Li, Weixing ^b   Zhang, Wanqiu ^b   Li, Yueying ^c   Zhu, Yichao ^a   Gu, Luo ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b TAIZHOU POLYTECHNIC COLLEGE   (China)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Arf6; EGF; ERK; GEP100; Invasion; UPAR

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; EPIDERMAL GROWTH FACTOR; GEP100 PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR INVASION;

EID: 84879885822     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.028     Document Type: Article

References (46)

1. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
3. Wells A., Kassis J., Solava J., Turner T., Lauffenburger D.A. Growth factor-induced cell motility in tumor invasion. Acta Oncol. 2002, 41:124-130.
4. Morishige M., Hashimoto S., Ogawa E., Toda Y., Kotani H., Hirose M., Wei S., Hashimoto A., Yamada A., Yano H., Mazaki Y., Kodama H., Nio Y., Manabe T., Wada H., Kobayashi H., Sabe H. GEP100 links epidermal growth factor receptor signaling to Arf6 activation to induce breast cancer invasion. Nat. Cell Biol. 2008, 10:85-92.
5. Menju T., Hashimoto S., Hashimoto A., Otsuka Y., Handa H., Ogawa E., Toda Y., Wada H., Date H., Sabe H. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PLoS One 2011, 6:e25301.
6. Xie C.G., Wei S.M., Chen J.M., Xu X.F., Cai J.T., Chen Q.Y., Jia L.T. Down-regulation of GEP100 causes increase in E-cadherin levels and inhibits pancreatic cancer cell invasion. PLoS One 2012, 7:e37854.
7. Sabe H., Hashimoto S., Morishige M., Hashimoto A., Ogawa E. The EGFR-GEP100-Arf6 pathway in breast cancer: full invasiveness is not from the inside. Cell Adhes. Migr. 2008, 2:71-73.
8. Sabe H., Hashimoto S., Morishige M., Ogawa E., Hashimoto A., Nam J.M., Miura K., Yano H., Onodera Y. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis. Traffic 2009, 10:982-993.
9. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., Romer J. Plasminogen activation and cancer. Thromb. Haemost. 2005, 93:676-681.
10. El-Kott A.F., Khalil A.M., El-Kenawy Ael M. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. Int. Urol. Nephrol. 2004, 36:417-423.
11. Memarzadeh S., Kozak K.R., Chang L., Natarajan S., Shintaku P., Reddy S.T., Farias-Eisner R. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc. Natl. Acad. Sci. USA 2002, 99:10647-10652.
12. Andres S.A., Edwards A.B., Wittliff J.L. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J. Clin. Lab. Anal. 2012, 26:93-103.
13. Lee K.H., Choi E.Y., Hyun M.S., Kim J.R. Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Exp. Mol. Med. 2004, 36:57-64.
14. Smith H.W., Marshall C.J. Regulation of cell signaling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11:23-36.
15. Park J.S., Park J.H., Khoi P.N., Joo Y.E., Jung Y.D. MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. Carcinogenesis 2011, 32:175-181.
16. Baek M.K., Kim M.H., Jang H.J., Park J.S., Chung I.J., Shin B.A., Ahn B.W., Jung Y.D. EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells. Oncol. Rep. 2008, 20:1569-1575.
17. Baek M.K., Park J.S., Park J.H., Kim M.H., Kim H.D., Bae W.K., Chung I.J., Shin B.A., Jung Y.D. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett. 2010, 290:123-128.
18. Tushir J.S., D'Souza-Schorey C. ARF6-dependent activation of ERK and Rac1 modulates epithelial tubule development. EMBO J. 2007, 26:1806-1819.
19. Hu Z., Du J., Yang L., Zhu Y., Yang Y., Zheng D., Someya A., Gu L., Lu X. GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells. PLoS One 2012, 7:e38777.
20. Someya A., Sata M., Takeda K., Pacheco-Rodriguez G., Ferrans V.J., Moss J., Vaughan M. ARF-GEP(100), a guanine nucleotide-exchange protein for ADP-ribosylation factor 6. Proc. Natl. Acad. Sci. USA 2001, 98:2413-2418.
21. Tague S.E., Muralidharan V., D'Souza-Schorey C. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc. Natl. Acad. Sci. USA 2004, 101:9671-9676.
22. Li M., Ng S.S., Wang J., Lai L., Leung S.Y., Franco M., Peng Y., He M.L., Kung H.F., Lin M.C. EFA6A enhances glioma cell invasion through ADP ribosylation factor 6/extracellular signal-regulated kinase signaling. Cancer Res. 2006, 66:1583-1590.
23. Festuccia C., Angelucci A., Gravina G.L., Biordi L., Millimaggi D., Muzi P., Vicentini C., Bologna M. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb. Haemost. 2005, 93:964-975.
24. Henic E., Sixt M., Hansson S., Hoyer-Hansen G., Casslen B. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol. Oncol. 2006, 101:28-39.
25. Jo M., Thomas K.S., Takimoto S., Gaultier A., Hsieh E.H., Lester R.D., Gonias S.L. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 2007, 26:2585-2594.
26. Henic E., Noskova V., Hoyer-Hansen G., Hansson S., Casslen B. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int. J. Gynecol. Cancer 2009, 19:214-222.
27. Vial E., Sahai E., Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003, 4:67-79.
28. Ikeda S., Ushio-Fukai M., Zuo L., Tojo T., Dikalov S., Patrushev N.A., Alexander R.W. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 2005, 96:467-475.
29. Zhang Q., Calafat J., Janssen H., Greenberg S. ARF6 is required for growth factor- and rac-mediated membrane ruffling in macrophages at a stage distal to rac membrane targeting. Mol. Cell. Biol. 1999, 19:8158-8168.
30. Bornancin F., Audigier Y., Chabre M. ADP-ribosylation of Gs by cholera toxin is potentiated by agonist activation of beta-adrenergic receptors in the absence of GTP. J. Biol. Chem. 1993, 268:17026-17029.
31. Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J. Biochem. 2003, 134:485-489.
32. Muralidharan-Chari V., Hoover H., Clancy J., Schweitzer J., Suckow M.A., Schroeder V., Castellino F.J., Schorey J.S., D'Souza-Schorey C. ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. Cancer Res. 2009, 69:2201-2209.
33. Lu J.T., Zhao W.D., He W., Wei W. Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway. Acta Pharmacol. Sin. 2012, 33:691-700.
34. Wang Y., Zhu Y., Zhang L., Tian W., Hua S., Zhao J., Zhang H., Xue F. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 2012, 322:223-231.
35. He X., Zheng Z., Li J., Ben Q., Liu J., Zhang J., Ji J., Yu B., Chen X., Su L., Zhou L., Liu B., Yuan Y. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis 2012, 33:555-562.
36. Cheng X., Shen Z., Yin L., Lu S.H., Cui Y. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009, 284:30897-30906.
37. Cheng X., Lu S.H., Cui Y. ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration. Cancer Lett. 2010, 290:87-95.
38. Nowicki T.S., Zhao H., Darzynkiewicz Z., Moscatello A., Shin E., Schantz S., Tiwari R.K., Geliebter J. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011, 10:100-107.
39. Gellert G.C., Kitson R.P., Goldfarb R.H. Urokinase-type plasminogen activator receptor crosslinking in an NK cell line increases integrin surface expression by the MAP kinase/ERK 1/2 signaling pathway. J. Cell Biochem. 2003, 89:279-288.
40. Aguirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K., Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 2001, 12:863-879.
41. Raghu H., Gondi C.S., Dinh D.H., Gujrati M., Rao J.S. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol. Cancer 2011, 10:130.
42. Ahmed N., Riley C., Oliva K., Rice G., Quinn M. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br. J. Cancer 2005, 92:1475-1485.
43. Ryu J., Ku B.M., Lee Y.K., Jeong J.Y., Kang S., Choi J., Yang Y., Lee D.H., Roh G.S., Kim H.J., Cho G.J., Choi W.S., Kim N., Kang S.S. Resveratrol reduces TNF-alpha-induced U373MG human glioma cell invasion through regulating NF-kappaB activation and uPA/uPAR expression. Anticancer Res. 2011, 31:4223-4230.
44. Harvey T.J., Burdon D., Steele L., Ingram N., Hall G.D., Selby P.J., Vile R.G., Cooper P.A., Shnyder S.D., Chester J.D. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Ther. 2010, 17:1000-1010.
45. Hu Z., Jiang X., Xu Y., Lu N., Wang W., Luo J., Zou H., Zheng D., Feng X. Downregulation of galectin-3 by EGF mediates the apoptosis of HepG2 cells. Mol. Cell Biochem. 2012, 369:157-165.
46. Du J., Xu R., Hu Z., Tian Y., Zhu Y., Gu L., Zhou L. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1alpha expression in MCF-7 breast cancer cells. PLoS One 2011, 6:e25213.